In 2012 40 brand name drugs with sales value of $35 billion lost patent protection. In 2013 this figure falls to $17 billion, according to analysts at Credit Agricole Securities. This means the opportunities for generics makers is diminishing. This is leading to consolidation and specialization by generics makers.